Alnylam Pharmaceuticals (NasdaqGS:ALNY) FY Conference September 10, 2025 12:20 PM ET Company ParticipantsJeff Poulton - CFOMichael Ulz - Executive Director - Biotechnology Equity ResearchMichael UlzAll right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Gold, one of the biotech analysts here, and it's my pleasure to introduce Jeff Poulton, CFO of Alnylam Pharmaceuticals. Before we get started, I just need to read a quick disclosure. For imp ...

Key Takeaways Alnylam and Roche reported positive phase II KARDIA-3 data on zilebesiran in hypertension patients.The 300 mg dose reduced SBP at 3 and 6 months, sustaining effects throughout the 24-hour cycle.Zilebesiran showed biomarker improvements and a mild-to-moderate safety profile, supporting phase III plans.Alnylam Pharmaceuticals (ALNY) and partner, Roche (RHHBY) , reported positive results from a mid-stage study, evaluating the efficacy and safety of zilebesiran in patients with uncontrolled hypert ...

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Congress 2025, zilebesiran demonstrated clinically meaningful reductions in office systolic blood pressure at month three with continuous control through month sixZilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrate ...